Tipifarnib in Treating Patients With Myelodysplastic Syndromes
This study has suspended participant recruitment.
(No information provided)
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00005845
First received: June 2, 2000
Last updated: January 16, 2013
Last verified: January 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This phase I trial studies the side effects and best dose of tipifarnib in treating patients with myelodysplastic syndromes. Tipifarnib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth
| Condition | Intervention | Phase |
|---|---|---|
|
Chronic Myelomonocytic Leukemia de Novo Myelodysplastic Syndromes Previously Treated Myelodysplastic Syndromes Refractory Anemia Refractory Anemia With Excess Blasts Refractory Anemia With Excess Blasts in Transformation Refractory Anemia With Ringed Sideroblasts Refractory Cytopenia With Multilineage Dysplasia |
Drug: tipifarnib Other: laboratory biomarker analysis Other: pharmacological study |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Phase I Study of the Farnesyl Transferase Inhibitor R115777 (NSC #702818) in Patients With Myelodysplastic Syndrome |
Resource links provided by NLM:
Further study details as provided by National Cancer Institute (NCI):
Primary Outcome Measures:
- MTD defined as the next lower dose level at which 2 patients experience dose limiting toxicity (DLT) defined as grade 3 or 4 toxicity according to the Cancer Therapy Evaluation Program Common Toxicity Criteria [ Time Frame: Up to 8.5 years ] [ Designated as safety issue: Yes ]The final analysis will report all toxicities by grade, dose, cycle, and by cumulative dose.
- Response rate [ Time Frame: Up to 8.5 years ] [ Designated as safety issue: No ]Will be reported overall and by dose level.
Secondary Outcome Measures:
- FTase inhibition [ Time Frame: Up to 8.5 years ] [ Designated as safety issue: No ]Based on the shape of the relationship (e.g. linear vs saturation vs peak), a dose response analysis will be performed to describe/summarize the relationship (correlation analysis or curve-fitting).
- Accumulation of unfarnesylated lamin B1 [ Time Frame: Up to 8.5 years ] [ Designated as safety issue: No ]Based on the shape of the relationship (e.g. linear vs saturation vs peak), a dose response analysis will be performed to describe/summarize the relationship (correlation analysis or curve-fitting).
- Accumulation of RAS proteins [ Time Frame: Up to 8.5 years ] [ Designated as safety issue: No ]Based on the shape of the relationship (e.g. linear vs saturation vs peak), a dose response analysis will be performed to describe/summarize the relationship (correlation analysis or curve-fitting).
| Estimated Enrollment: | 65 |
| Study Start Date: | June 2002 |
| Primary Completion Date: | December 2006 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Treatment (tipifarnib)
Patients receive tipifarnib PO BID on weeks 1, 3, 5, and 7. Treatment repeats every 8 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.
|
Drug: tipifarnib
Given PO
Other Names:
Other: laboratory biomarker analysis
Correlative studies
Other: pharmacological study
Correlative studies
Other Name: pharmacological studies
|
Detailed Description:
PRIMARY OBJECTIVES:
I. To determine the toxicity profile and antitumor activity of the farnesyltransferase (FTase) inhibitor R115777 (tipifarnib) in patients with myelodysplastic syndrome (MDS) treated on a one week on/one week off schedule.
II. To determine the effect on R115777 on a one week on/one week off schedule on FTase activity, prenylation of RAS and other substrates and on downstream effects.
OUTLINE: This is a dose-escalation study.
Patients receive tipifarnib orally (PO) twice daily (BID) on weeks 1, 3, 5, and 7. Treatment repeats every 8 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
Patients must have histologically MDS (including French-American-British [FAB] types refractory anemia [RA], refractory anemia with ringed sideroblasts [RARS], refractory anemia with excess blasts [RAEB], refractory anemia with excess blasts in transformation [RAEBT], or chronic myelomonocytic leukemia [CMMoL]); for the purpose of the study, all patients will be classified by World Health Organization (WHO) criteria
- By these criteria, FAB RA are split into:
Pure dyserythropoietic refractory anemia (PRA)
- Refractory cytopenia with multilineage dysplasia (RCMD)
FAB RARS is split into:
- Pure sideroblastic anemia (PSA)
- Refractory sideroblastic cytopenia with multilineage dysplasia (RSCMD)
FAB RAEB is split into:
- RAEB I (< 10% BM blasts)
- RAEB II (10-20% BM blasts)
- Patients with CMMoL, and RAEBT by FAB classification will be included in the protocol
- Prognosis will be assessed by International Prognostic Scoring System (IPSS) criteria
- =< 2 prior therapies
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2
- Life expectancy of greater than 12 weeks
- Bilirubin =< 1.5mg %
- Creatinine =< 1.5mg %
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Patients who have had chemotherapy or radiotherapy within 4 weeks (3 months for UCN01) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
- Patients may not be receiving any other investigational agents
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to R115777 (such as imidazoles)
- Patients eligible for bone marrow transplant (=< 60 years old), with a compatible sibling, no contraindications for transplant
- Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with R115777.
- Growth factors other than filgrastim (G-CSF) are excluded; patients should be off excluded growth factors for 2 weeks
Contacts and Locations More Information
No publications provided
| Responsible Party: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT00005845 History of Changes |
| Other Study ID Numbers: | NCI-2009-01158, DM01-582, U01CA062461, CDR0000067862 |
| Study First Received: | June 2, 2000 |
| Last Updated: | January 16, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Anemia Anemia, Refractory Anemia, Refractory, with Excess of Blasts Leukemia Leukemia, Myelomonocytic, Chronic Myelodysplastic Syndromes Preleukemia Leukemia, Myelomonocytic, Acute Anemia, Aplastic Hematologic Diseases |
Bone Marrow Diseases Neoplasms by Histologic Type Neoplasms Leukemia, Myeloid Myelodysplastic-Myeloproliferative Diseases Precancerous Conditions Tipifarnib Antineoplastic Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 23, 2013